Chinese guidelines for treatment of adult primary immune thrombocytopenia
- 845 Downloads
Primary immune thrombocytopenia (ITP) is a bleeding disorder commonly encountered in clinical practice. The International Working Group (IWG) on ITP has published several landmark papers on terminology, definitions, outcome criteria, bleeding assessment, diagnosis, and management of ITP. The Chinese consensus reports for diagnosis and management of adult ITP have been updated to the 4th edition. Based on current consensus positions and new emerging clinical evidence, the thrombosis and hemostasis group of the Chinese Society of Hematology issued Chinese guidelines for management of adult ITP, which aim to provide evidence-based recommendations for clinical decision making.
KeywordsPrimary immune thrombocytopenia Guideline Diagnosis, management
Alexandra H. Marshall (of Marshall Medical Communications) provided editorial assistance to the authors during preparation of this manuscript.
Compliance with ethical standards
Conflict of interest
The authors have no competing financial interests to declare.
- 7.Chinese Society of Hematology GoTaH. Consensus Of Chinese Specialists On the diagnosis and treatment of the adult primary immune thrombocytopenia. Chin J Hematol. 2012;33(11):975–7.Google Scholar
- 8.Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–93.CrossRefPubMedGoogle Scholar
- 9.Thrombosis, Hemostasis Group HSCMA. Consensus of Chinese experts on diagnosis and treatment of adult primary immune thrombocytopenia (version 2016). Zhonghua Xue Ye Xue Za Zhi. 2016;37(2):89–93.Google Scholar
- 12.Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of aplastic anemia (2017. Zhonghua Xue Ye Xue Za Zhi. 2017;38(1):1–5.Google Scholar
- 22.Hua B, Zhao Y, Wang S, Zhu T, Zhao Y. Development of recombinant human thrombopoietin antibodies following multi-dosing, subcutaneously medication in thrombocytopenic patients. Chin J Thromb Hemostasis. 2005;11(2):59–61.Google Scholar
- 24.Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2009;373(9664):641–8.CrossRefGoogle Scholar
- 29.Mazza P, Minoia C, Melpignano A, Polimeno G, Cascavilla N, Di Renzo N, et al. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Ann Hematol. 2016;95(2):239–44.CrossRefPubMedGoogle Scholar
- 43.Bussel JB, Lee CS, Seery C, Imahiyerobo AA, Thompson MV, Catellier D, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than 2 years duration. Haematologica. 2014;99(7):1264–71.CrossRefPubMedPubMedCentralGoogle Scholar